$90.00 - $90.00
Angiotensin II Antipeptide is an eight-residue synthetic peptide with the sequence Glu-Gly-Val-Tyr-Val-His-Pro-Val (EGVYVHPV). The sequence originated from early antisense-peptide research in which a peptide encoded by complementary mRNA to human angiotensin II mRNA was investigated for functional interactions with the angiotensin signaling system.
The molecule provides a distinctive research tool for studying historical antipeptide concepts, angiotensin-dependent smooth-muscle responses and peptide–receptor modulation.
Product Information
| Property | Specification |
|---|---|
| Product Name | Angiotensin II Antipeptide |
| Catalog No. | AS2614 |
| CAS No. | 121379-63-3 |
| Sequence | Glu-Gly-Val-Tyr-Val-His-Pro-Val |
| One-Letter Sequence | EGVYVHPV |
| Peptide Length | 8 amino acids |
| Molecular Formula | C42H62N10O12 |
| Molecular Weight | Approximately 899.02 Da |
| Research Context | Angiotensin antipeptide and receptor-modulation studies |
| Purity | Crude to 98% |
Origin of the Antipeptide Sequence
EGVYVHPV was derived from a complementary coding concept rather than from proteolytic processing of angiotensinogen.
Foundational studies reported inhibition of angiotensin-induced smooth-muscle responses and proposed interaction with a modulatory receptor site. This work forms the historical basis for describing EGVYVHPV as an Angiotensin II Antipeptide.
We recommend retaining this historical context when designing experiments. The peptide should not be grouped automatically with modern non-peptide AT1 receptor blockers or assumed to share their pharmacological mechanism.
Research Applications
Angiotensin II Antipeptide can support investigations of peptide complementarity, angiotensin-dependent contractile responses, receptor modulation and historical antisense-peptide hypotheses.
Its sequence also provides a useful scaffold for comparative studies against native angiotensin-family peptides with different N-terminal and C-terminal recognition features.
Experimental Planning
Biological effects reported for antipeptides depend on tissue preparation, receptor system, peptide concentration and assay format. Direct receptor-binding or functional controls are appropriate when the mechanism of action is an experimental endpoint.
Related cardiovascular research peptides can be explored in our Cardiovascular Peptides collection.
Frequently Asked Questions
Is Angiotensin II Antipeptide another name for Angiotensin II?
No. Angiotensin II has the sequence DRVYIHPF, while the antipeptide sequence is EGVYVHPV.
Is this peptide a conventional AT1 receptor blocker?
No. Its research history comes from antisense-peptide studies and proposed receptor-modulatory activity. It should be evaluated as a distinct peptide reagent.
Can antipeptide variants be prepared?
Sequence substitutions and modified analogs can be evaluated through Chemical Peptide Synthesis.